← ANALYST RATINGS · TIPRANKS
RegenXBio (RGNX): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy2 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $21.73, the highest $42.00, the lowest $10.00. The average is +213.8% from the last price of $6.92.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $12.00 | Hold | +73.3% | Reiterated | 13.10.26on TipRanks 04:50 | −6.6%next day −4.2% | ↗ |
| Lili (Aurélie) Nsongo★★★★★★★★★★#12236 · hits 10% · avg −32.8% | Leerink Partners | $19.00 | Buy | +174.4% | Reiterated | 12.10.26on TipRanks Oct 13 01:16 | −3.7%next day −6.6% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $22.00 | Buy | +217.7% | Initiated | 05.10.26on TipRanks 04:55 | +3.8%next day −4.5% · 5 days −0.3% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $21.00 | Buy | +203.2% | Reiterated | 25.09.26on TipRanks Sep 28 06:30 | +1.7%next day +1.7% · 5 days +0.6% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $42.00 | Buy | +506.5% | Reiterated | 25.09.26on TipRanks 07:30 | +1.7%next day +1.7% · 5 days +0.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $8.00+6.7% | Hold | +15.5% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $8.00+6.7% | Hold | +15.5% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $8.00+6.7% | Hold | +15.5% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.00 → $7.50+7.1% | Sell | +8.3% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $8.00+6.7% | Hold | +15.5% | Upgrade | 23.09.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $8.00+6.7% | Hold | +15.5% | Reiterated | 23.09.26on TipRanks 19:05 | — | |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $15.00 | Buy | +116.6% | Reiterated | 21.09.26on TipRanks 07:55 | −3.4%next day +3.4% · 5 days −4.2% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $32.00 → $29.00−9.4% | Buy | +318.8% | Reiterated | 25.08.26on TipRanks 06:30 | +10.3%next day +5.3% · 5 days +5.1% | ↗ |
| Mara Goldstein★★★★★★★★★★#12071 · hits 34% · avg −5.0% | Mizuho Securities | $45.00 → $32.00−28.9% | Buy | +362.1% | Reiterated | 25.08.26on TipRanks Aug 24 22:10 | +10.3%next day +5.3% · 5 days +5.1% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $10.00 | Hold | +44.4% | Reiterated | 24.08.26on TipRanks Aug 25 08:10 | −24.6%next day +10.3% · 5 days +17.5% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $18.00 | Buy | +159.9% | Reiterated | 24.08.26on TipRanks Aug 25 07:26 | −24.6%next day +10.3% · 5 days +17.5% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $12.00 | Hold | +73.3% | Downgrade | 07.08.26on TipRanks 04:19 | −5.6%next day −2.8% · 5 days 0.0% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $19.00 | Buy | +174.4% | Reiterated | 06.08.26on TipRanks Aug 7 07:26 | +7.6%next day −5.6% · 5 days −6.7% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $18.00 → $17.00−5.6% | Buy | +145.5% | Reiterated | 15.05.26on TipRanks 11:20 | −7.2%next day −1.2% · 5 days +10.1% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $52.00 | Buy | +650.9% | Reiterated | 28.01.26on TipRanks 18:10 | +5.6%next day −3.5% · 5 days −9.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering RegenXBio
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.00 at a price of $7.53 (+192.2%); now: $21.73 at $6.92 (+213.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 12 | 14 | 17 | 15 | 15 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 3 | 1 | 1 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.24 (from $-1.63 to $-0.68). Last quarter: $0.43.
Sales
Next quarter’s sales estimate — $15M (from $6M to $51M). Last quarter: $108M.
Best top-analyst consensus in the sector · Healthcare
About RegenXBio
- CEO: Curran Simpson
- Employees: 371
- 9804 Medical Center Drive, Rockville, MD, 20850, US
- www.regenxbio.com
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Data from the stock’s TipRanks forecast page, read 12 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗